Latest News
FDA Approves Juvmo (tavapadon) for the Treatment of Parkinson's Disease
NORTH CHICAGO, Ill., Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Juvmo (tavapadon) tablets as the first and only se
FDA Approves Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE) September 25, 2026 -- Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Adminis
FDA Approves Degevma (denosumab-adet), a Biosimilar to Xgeva
TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) ha
FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder
September 29, 2026 -- Azurity Pharmaceuticals, a privately held global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administr
FDA Approves Onswik (insulin efsitora alfa-gobe) Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
INDIANAPOLIS, Sept. 24, 2026 /PRNewswire/ -- Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insu
FDA Approves Lyrfigtu (lirafugratinib) for the Treatment of Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
FORT LEE, N.J., September 23, 2026 -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experien
FDA Approves Bravnetsa (lutetium Lu 177 dotatate) as a Therapeutic Equivalent to Lutathera for the Treatment of Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors in Adults
BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed t
FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
NOVATO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) granted standard full approval of Fayu
FDA Approves Bexlutry (lutetium Lu 177 dotatate) for Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors
Boston, MA – 14 September, 2026 -- Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Bexlutry™ lutetium Lu 177 dotatate injection
FDA Approves Pixclara (floretyrosine F 18) FET-PET Imaging Agent for Glioma
Melbourne (Australia) and Indianapolis, IN (United States) -- September 14, 2026 -- Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug App
FDA Approves Isembyld (apitegromab-mstn) Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE) -- September 11, 2026 -- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitat
FDA Grants Accelerated Approval to Etcamah (camizestrant) in Combination with a CDK4/6 Inhibitor for the Treatment of Advanced HR-Positive Breast Cancer
September 4, 2026 -- AstraZeneca’s Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the
News
- CanalLotus Biotech -
Int'l Clinical Service Expert
We are the leader
Because of our professionism











